Features

Marketers take a new approach to lung-cancer campaigns, and why that matters

Marketers take a new approach to lung-cancer campaigns, and why that matters

By

Each of the approaches is valid and more ambitious than a great majority of the campaigns that preceded them.

Merck and Aetna pair population health with risk-sharing, in two deals

Merck and Aetna pair population health with risk-sharing, in two deals

By

But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?

Ryan Abbate, 2017 MAHF inductee, sets the record straight

Ryan Abbate, 2017 MAHF inductee, sets the record straight

By

The founder of Pacific Communications shares the details of his career as he is inducted into the Medical Advertising Hall of Fame.

Mike Lazur, 2017 MAHF inductee, on his medical advertising destiny

Mike Lazur, 2017 MAHF inductee, on his medical advertising destiny

By

He played a leading role during Torre Lazur's glory era as "the launch agency." Now he is being inducted into the Medical Advertising Hall of Fame.

Trump administration raises questions for rare-disease drugmakers

Trump administration raises questions for rare-disease drugmakers

By

Nobody knows what the future holds for the Affordable Care Act under the Trump administration and an emboldened Republican Congress.

Shark Tank's Herjavec shares his tips for innovation competitions

Shark Tank's Herjavec shares his tips for innovation competitions

By

When his mother suffered from ovarian cancer a decade ago, Robert Herjavec found himself frustrated by the quality of care she received.

Japanese drugmakers lead the way in digital innovation

Japanese drugmakers lead the way in digital innovation

By

Otsuka, Astellas, Takeda, and Daiichi Sankyo share a degree of adventurousness and forward-mindedness in the digital realm.

5 digital experts on what's next in health technology

5 digital experts on what's next in health technology

Read more to learn what Startup Health's Unity Stoakes and UCB's Greg Cohen, and others have to say about the latest trends for 2017.

Pharma adopts data-science culture in move toward AI

Pharma adopts data-science culture in move toward AI

By

Data scientists are a new kind of insight and analytics professional showing up in the biopharma ranks.

Why healthbots may eat search ads and mobile apps

Why healthbots may eat search ads and mobile apps

By

The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.

Big data expert Hilary Mason on 3 ways to create a data-driven culture

Big data expert Hilary Mason on 3 ways to create a data-driven culture

By

The first step is to seek leadership support, she says.

The 2017 pipeline report: What to know about next year's launches

The 2017 pipeline report: What to know about next year's launches

By

Here's a look at 100 experimental therapies in late-stage clinical trials.

The doctor-patient dialogue: As productive as it's ever been or broken?

The doctor-patient dialogue: As productive as it's ever been or broken?

By

More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.

Infographic: The physician view on EHRs

Infographic: The physician view on EHRs

Most physicians said EHRs have negatively impacted their communication with a patients.

Evercore ISI's Umer Raffat on his predictions for pharma in 2017

Evercore ISI's Umer Raffat on his predictions for pharma in 2017

By

Specialty pharma ace Umer Raffat, a senior analyst at Evercore ISI, shares his 2016 postmortem and a few quick-hit predictions for 2017.

Will he or won't he? Pharma speculates on President-elect Trump

Will he or won't he? Pharma speculates on President-elect Trump

By

If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.

Drugmakers, facing pricing criticism, sell cures in new ads

Drugmakers, facing pricing criticism, sell cures in new ads

By

With lawmakers, patients, and physicians crying foul over pricing, drugmakers are trying to shift the narrative — with mixed results. Can a new focus on storytelling help?

Insurers seek to challenge millennial 'invincibility'

Insurers seek to challenge millennial 'invincibility'

By

Tech companies and Bernie Sanders have found the millennial audience easy to crack. Organizations in and around healthcare? Not so much.

3 health tech innovations experts say will revolutionalize healthcare

3 health tech innovations experts say will revolutionalize healthcare

By

As digital-health funding increases, here's how VR, nanotechnology, and 3D printing could potentially improve the value of healthcare.

What do employers want? We ask three execs for their secrets and their insights

What do employers want? We ask three execs for their secrets and their insights

They share their insights, secrets, worries, and everything else in between.

The industry's winning — and losing — job titles, based on salary

The industry's winning — and losing — job titles, based on salary

Hint: it pays to be an EVP.

Pharma marketing salaries veer off track, dropping 2.6% in 2016

Pharma marketing salaries veer off track, dropping 2.6% in 2016

By

Execs say that career prospects are better than ever. Yet data from MM&M's annual Career and Salary Survey reveals a decline in growth.

Sudler New York's John Marchese on the New Talent Pool

Sudler New York's John Marchese on the New Talent Pool

By

"It's easy to 'fill open positions,'" Marchese says. "We've banned that phrase. If you do that, you're just checking boxes on a list."

Diabetes marketers turn to big data, gaming to improve outcomes

Diabetes marketers turn to big data, gaming to improve outcomes

By

Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.

The co-pay card debate simmers, as payers push back

The co-pay card debate simmers, as payers push back

By

Will this payer pressure pose an existential threat to co-pay cards even though patients love them?

PBMs push forward toward outcomes-based pricing, despite challenges

PBMs push forward toward outcomes-based pricing, despite challenges

By

The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.

Healthcare marketers: Don't forget about the baby boomers

Healthcare marketers: Don't forget about the baby boomers

By

Baby boomers have taken to health tech with surprising ease, opening up a wealth of opportunities for marketers savvy enough to pursue them.

The CIO, reimagined for pharma

The CIO, reimagined for pharma

By

Despite the increasing importance of the CIO post, top technology professionals still find it hard to break into the uppermost ranks at life-sciences companies.

Leadership Exchange: Engaging the Millennial Doctor

Leadership Exchange: Engaging the Millennial Doctor

By

In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.

Telehealth: Improving the customer experience but still an unknown for pharma

Telehealth: Improving the customer experience but still an unknown for pharma

By

Although telehealth is still in its early stages, it's building momentum — with good reason.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

By

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

What do physicians think about biosimilars?

What do physicians think about biosimilars?

By

A Sermo poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"

2016 Pharma Report: All the data in one place

2016 Pharma Report: All the data in one place

Learn more about the top therapeutic categories by sales, top companies by revenue, top drugs by sales, and more.

Post Pfizer, Allergan faces the future

Post Pfizer, Allergan faces the future

By

Mere days after the Pfizer deal collapsed, top Allergan executives had nary an air of regret about them.

Spending on drugs is up, but by how much?

Spending on drugs is up, but by how much?

By

Total medicine spending surged to $424.8 billion in 2015, representing an increase of 12.2%. Here's why that growth figure is closer to 2.9%.

MM&M's Hall of Femme: 16 women leaders who changed the industry

MM&M's Hall of Femme: 16 women leaders who changed the industry

The 16 women profiled here number among those who have bridged the gender gap in agencies, biopharma, and medtech.

MM&M's Hall of Femme: 20 women to watch

MM&M's Hall of Femme: 20 women to watch

The MM&M Women to Watch, part of our inaugural Hall of Femme, salutes 20 aspiring healthcare commercial and marketing execs distinguishing themselves.

When it comes to professional ads, print makes its comeback

When it comes to professional ads, print makes its comeback

By

Following print's best year since 2011, it's time to rewrite those journal-advertising obituaries. Medical-surgical print journal spending in 2015 was up 8.4% to $372 million.

Which brands spent the most on professional ads in 2015?

Which brands spent the most on professional ads in 2015?

By

Here are the brands and companies that advertised the most on professional ads in 2015.

Retaining talent: How pharma can compete with Google

Retaining talent: How pharma can compete with Google

By

As tech behemoths like Google are attempting to poach the best and brightest, executives from pharma companies and agencies share new retention tactics.

How to win an MM&M award: the do's and the don'ts

How to win an MM&M award: the do's and the don'ts

Tip: Don't charge your intern with assembling your entry. Read more from our checklists of do's and don'ts, and don't forget that entries are due April 11.

Healthcare industry seeks to reform its position as hacking target

Healthcare industry seeks to reform its position as hacking target

Given the value of its data and its relatively backward security measures, the healthcare industry has become a prime target for hackers. But industry experts say changes are afoot.

Pharma turns to mobile, population data to market to docs

Pharma turns to mobile, population data to market to docs

By

Discover why even digitally native physicians can no longer abide the flood of information e-sent their way.

Sensors, technology open the door to new era for clinical trials

Sensors, technology open the door to new era for clinical trials

By

Welcome to the mobile era for clinical trials, in which phone and tablet technology promise to upend a costly and unwieldy process.

Drugmakers partner in immuno-oncology, to better capture market share

Drugmakers partner in immuno-oncology, to better capture market share

By

Manufacturers team up to study drug combinations, a strategy expected to advance the category.

Celebrity pharma ads: Opportunity or PR disaster?

Celebrity pharma ads: Opportunity or PR disaster?

By

Tapping celebrities for brand or awareness campaigns ensures a high degree of attention, but such arrangements come with concerns that "regular" ones do not.

Medical Advertising Hall of Fame inductees of 2016

Medical Advertising Hall of Fame inductees of 2016

By

A pharma research forefather. An agency builder. A "guy you wanted in the room." These Medical Advertising Hall of Fame inductees are a professionally diverse and richly worthy trio.

Making the Case for the Value of Co-pay Cards

Making the Case for the Value of Co-pay Cards

Now that payers are locking in discounts at launch from drugmakers, where do co-pay cards fit in the marketing mix?

With PCSK9s, payers say, 'Let the market decide'

With PCSK9s, payers say, 'Let the market decide'

By

It's possible that payers won't prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers' hands.

 MM&M's Top 40 Healthcare Transformers of 2016

MM&M's Top 40 Healthcare Transformers of 2016

Here are the 40 executives, investors, entrepreneurs, designers and thinkers who are ushering the industry into its new technological golden era.

OPINION

Newsletters